The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | PD-1 & PDL-1 combinations with CAR T-cell therapy
David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA., discusses the safety and efficacy regarding the combination of various agents with CAR T-cell therapy, notably checkpoint inhibitors for PD-1 and PDL-1, which offer a bright future for those who relapse after CAR T-cell therapy, though it is still early days. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
